Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation

Clin Lung Cancer. 2021 Sep;22(5):e712-e715. doi: 10.1016/j.cllc.2021.01.015. Epub 2021 Feb 3.
No abstract available

Keywords: NTRK fusion; Osimertinib resistance; Targeted therapy.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / pharmacology*
  • Acrylamides / therapeutic use*
  • Adenocarcinoma of Lung / drug therapy*
  • Aged
  • Aniline Compounds / pharmacology*
  • Aniline Compounds / therapeutic use*
  • Female
  • Humans
  • Receptor, Notch2 / drug effects*
  • Receptor, trkA / drug effects*

Substances

  • Acrylamides
  • Aniline Compounds
  • NOTCH2 protein, human
  • NTRK1 protein, human
  • Receptor, Notch2
  • osimertinib
  • Receptor, trkA